Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.

Ling YH, Li T, Perez-Soler R, Haigentz M Jr.

Cancer Chemother Pharmacol. 2009 Aug;64(3):539-48. doi: 10.1007/s00280-008-0902-8. Epub 2009 Jan 8.

PMID:
19130057
2.

Targeting STAT3 in cancer: how successful are we?

Yue P, Turkson J.

Expert Opin Investig Drugs. 2009 Jan;18(1):45-56. doi: 10.1517/13543780802565791 . Review.

3.

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S.

Cancer Res. 2008 Nov 15;68(22):9479-87. doi: 10.1158/0008-5472.CAN-08-1643.

4.

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA.

Clin Cancer Res. 2008 Nov 1;14(21):6963-73. doi: 10.1158/1078-0432.CCR-08-0957.

5.

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Mol Cancer Ther. 2008 Nov;7(11):3499-508. doi: 10.1158/1535-7163.MCT-08-0374. Epub 2008 Oct 30.

6.

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS.

Cancer Res. 2008 Oct 15;68(20):8322-32. doi: 10.1158/0008-5472.CAN-07-6720.

7.

Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network.

Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA.

Proteomics. 2008 Nov;8(21):4383-401. doi: 10.1002/pmic.200800204. Review.

PMID:
18846509
8.

EGFR family: structure physiology signalling and therapeutic targets.

Burgess AW.

Growth Factors. 2008 Oct;26(5):263-74. doi: 10.1080/08977190802312844. Review.

PMID:
18800267
9.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R.

N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.

10.

PTEN-deficient cancers depend on PIK3CB.

Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62. doi: 10.1073/pnas.0802655105. Epub 2008 Aug 28.

11.

Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma.

Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, Beder LB, Demircan K, Fujii M, Yamanaka N, Shimizu K, Grenman R, Nagai N.

Cancer Sci. 2008 Aug;99(8):1589-94. doi: 10.1111/j.1349-7006.2008.00861.x.

12.

Akt pathway as a target for therapeutic intervention in HNSCC.

Moral M, Paramio JM.

Histol Histopathol. 2008 Oct;23(10):1269-78. doi: 10.14670/HH-23.1269. Review.

PMID:
18712679
13.

Skp2, p27kip1 and EGFR assessment in head and neck squamous cell carcinoma: prognostic implications.

Carracedo DG, Astudillo A, Rodrigo JP, Suarez C, Gonzalez MV.

Oncol Rep. 2008 Sep;20(3):589-95.

PMID:
18695910
14.

Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation.

Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP.

Dev Cell. 2008 Aug;15(2):209-19. doi: 10.1016/j.devcel.2008.06.012.

15.

Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab.

Kondo N, Ishiguro Y, Kimura M, Sano D, Fujita K, Sakakibara A, Taguchi T, Toth G, Matsuda H, Tsukuda M.

Oncol Rep. 2008 Aug;20(2):373-8.

PMID:
18636200
16.

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

Prat A, Baselga J.

Nat Clin Pract Oncol. 2008 Sep;5(9):531-42. doi: 10.1038/ncponc1179. Epub 2008 Jul 8. Review.

PMID:
18607391
17.

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.

Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ.

Nature. 2008 Aug 7;454(7205):776-9. doi: 10.1038/nature07091. Epub 2008 Jun 25. Erratum in: Nature. 2016 May 12;533(7602):278.

18.

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR.

Clin Cancer Res. 2008 Jul 1;14(13):4284-91. doi: 10.1158/1078-0432.CCR-07-5226.

19.

Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression.

Hung LY, Tseng JT, Lee YC, Xia W, Wang YN, Wu ML, Chuang YH, Lai CH, Chang WC.

Nucleic Acids Res. 2008 Aug;36(13):4337-51. doi: 10.1093/nar/gkn417. Epub 2008 Jun 27.

20.

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.

Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G.

Br J Cancer. 2008 Jul 8;99(1):93-9. doi: 10.1038/sj.bjc.6604429. Epub 2008 Jun 24.

Supplemental Content

Support Center